Harbin Pharmaceutical Group Co., Ltd.

Harbin Pharmaceutical Group Co., Ltd. has seen substantial stock price growth, with a notable increase on August 10, 2026. Over the past week and month, the company has significantly outperformed the China Shanghai Composite, despite facing challenges such as declining earnings per share and lower operating cash flow.

Harbin Pharmaceutical Group Co., Ltd. has shown remarkable stock performance, significantly outperforming the China Shanghai Composite. Over the past week and month, the company has recorded substantial gains, despite facing challenges in financial metrics. Its market capitalization is CNY 7,830 million, with a P/E ratio of 23.00.

Harbin Pharmaceutical Group Co., Ltd. saw a notable increase in its stock performance on July 17, 2026, achieving an intraday high amid a declining broader market. Despite recent gains, the company faces challenges, including a decline in earnings per share and lower operating cash flow, reflecting mixed long-term performance.

Harbin Pharmaceutical Group Co., Ltd. has seen a notable rise in stock performance, particularly on July 13, 2026. The company has outperformed the China Shanghai Composite index over various periods, despite facing challenges such as declining earnings per share and lower operating cash flow. Its current market capitalization is CNY 7,830 million.

Harbin Pharmaceutical Group Co., Ltd. saw a notable increase in its stock performance on July 10, 2026, reaching an intraday high amid a declining market. Despite facing longer-term challenges, the company has outperformed the China Shanghai Composite over the past five years, showcasing resilience in a fluctuating environment.

Harbin Pharmaceutical Group Co., Ltd. saw a notable decline in its stock performance, with a significant drop today and a continued downward trend over the past week and month. Key financial metrics reveal a sharp decrease in earnings per share and operating cash flow, indicating ongoing challenges for the company.